Latest Articles
Selinexor Misses Primary Endpoint in Endometrial Cancer Trial - empr.com
Selinexor Misses Primary Endpoint in Endometrial Cancer Trial empr.com
Published: July 31, 2026, 4 a.m.
MRI in non-pregnancy-related decidualization of deep pelvic endometriosis: a case report and review of the literature.
Decidual changes in deep pelvic endometriosis (DPE) are extremely rare. During pregnancy, endometriotic activity and symptoms diminish due to hormonal changes, whereas the endometrial lining undergoes decidualization in response to …
Published: July 31, 2026, midnight
Karyopharm plummets as Xpovio fails in phase 3 trial for endometrial cancer - Seeking Alpha
Karyopharm plummets as Xpovio fails in phase 3 trial for endometrial cancer Seeking Alpha
Published: July 30, 2026, 11:38 p.m.
Karyopharm slumps after Xpovio misses mark in Phase III endometrial cancer study - FirstWord Pharma
Karyopharm slumps after Xpovio misses mark in Phase III endometrial cancer study FirstWord Pharma
Published: July 30, 2026, 9:59 p.m.
Karyopharm’s endometrial cancer candidate did not meet Phase 3 primary endpoint - TipRanks
Karyopharm’s endometrial cancer candidate did not meet Phase 3 primary endpoint TipRanks
Published: July 30, 2026, 9:16 p.m.
Karyopharm’s endometrial cancer candidate did not meet Phase 3 primary endpoint - tipranks.com
Karyopharm’s endometrial cancer candidate did not meet Phase 3 primary endpoint tipranks.com
Published: July 30, 2026, 9:16 p.m.
Karyopharm endometrial cancer trial misses primary endpoint By Investing.com - Investing.com Nigeria
Karyopharm endometrial cancer trial misses primary endpoint By Investing.com Investing.com Nigeria
Published: July 30, 2026, 8:42 p.m.
Karyopharm endometrial cancer trial misses primary endpoint - Investing.com
Karyopharm endometrial cancer trial misses primary endpoint Investing.com
Published: July 30, 2026, 8:31 p.m.
Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer - Karyopharm
Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer Karyopharm
Published: July 30, 2026, 8:09 p.m.
Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer - marketscreener.com
Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer marketscreener.com
Published: July 30, 2026, 8:07 p.m.
Link copied to clipboard!